A Novel Recombinant Vitronectin Variant Supports the Expansion and Differentiation of Pluripotent Stem Cells in Defined Animal-Free Workflows
Cells · 2024
DOI: 10.3390/cells13181566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Xi Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell & Gene Therapy, Bio-Techne, Minneapolis, MN 55413, USA. Hauptthemen laut MEDLINE: Vitronectin, Cell Differentiation, Induced Pluripotent Stem Cells, Recombinant Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
An essential aspect of harnessing the potential of pluripotent stem cells (PSCs) and their derivatives for regenerative medicine is the development of animal-free and chemically defined conditions for ex vivo cultivation. PSCs, including embryonic and induced PSCs (iPSCs), are in the early stages of clinical trials for various indications, including degenerative diseases and traumatic injury. A key step in the workflows generating these cells for more widespread clinical use is their safe and robust ex vivo cultivation. This entails optimization of cell culture media and substrates that are safe and consistent while maintaining robust functionality. Here, we describe the design of a human vitronectin (hVTN) variant with improved manufacturability in a bacterial expression system along with improved function in comparison to wild-type VTN and other previously characterized polypeptide fragments. In conjunction with an animal component-free media formulation, our hVTN fragment provides animal-free conditions for the enhanced expansion of iPSCs. This hVTN variant also supports the reprogramming of PBMCs into iPSCs. Furthermore, we show that these iPSCs can be efficiently differentiated into the three major germ layers and cortical neurons, thereby closing the loop on a completely defined animal-free workflow for cell types relevant for regenerative medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cell & Gene Therapy, Bio-Techne, Minneapolis, MN 55413, USA.
- Protein Development, Bio-Techne, Minneapolis, MN 55413, USA.
- Antibody Applications, Bio-Techne, Minneapolis, MN 55413, USA.
- Department of Biochemistry & Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA.
ORCID-Profile: Alex Kalyuzhny
Zitieren
APA
Lu, X., Perr, E., Naqvi, T., Galitz, D., Andersen, M., Grabowski, D., Person, A., Kalyuzhny, A., & Flynn, K. C. (2024). A Novel Recombinant Vitronectin Variant Supports the Expansion and Differentiation of Pluripotent Stem Cells in Defined Animal-Free Workflows. Cells. https://doi.org/10.3390/cells13181566
Vancouver
Lu X, Perr E, Naqvi T, Galitz D, Andersen M, Grabowski D, et al. A Novel Recombinant Vitronectin Variant Supports the Expansion and Differentiation of Pluripotent Stem Cells in Defined Animal-Free Workflows. Cells. 2024. doi:10.3390/cells13181566
BibTeX
@article{Lu2024,
author = {Lu, Xi and Perr, Eli and Naqvi, Tahmina and Galitz, David and Andersen, Marnelle and Grabowski, David and Person, Anthony and Kalyuzhny, Alex and Flynn, Kevin C},
title = {A Novel Recombinant Vitronectin Variant Supports the Expansion and Differentiation of Pluripotent Stem Cells in Defined Animal-Free Workflows},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13181566}
}
EUVIMED